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Abstract 
Several studies have been conducted with the aim of investigating the effect of ω-3 on different 
psoriasis indices including Psoriasis Area and Severity Index (PASI) score, erythema, scaling, 
itching, area involved and infiltration. Nevertheless, a pooled analysis of trials that evaluated 
these variables has not been conducted. Therefore, the aim of this meta-analysis was to assess the 
efficacy of ω-3 fatty acids in treating patients with psoriasis. We searched through different 
electronic, references of retrieved articles and previous related reviews databases up to 
November 2018. Both combined and stratified analyzes were conducted. A fixed-effects or 
random-effects model was used to assess the mean effect sizes. An eventual 10 studies involving 
560 participants were considered as eligible for inclusion in the present meta-analysis. The meta-
analysis indicated a significant reduction in PASI score by −1.58 (95% CI: -2.24, -0.92; P < 
0.001) in favor of ω-3 PUFA group. The random-effect model showed a statistically significant 
beneficial effect of ω-3 PUFA supplementation on reducing erythema by -1.66 unit and reducing 
scaling [WMD: -0.69, 95% CI: -1.26, -0.13, P = 0.02). Significant improvements in erythema, 
itching, and scale were observed in the trials which used the higher-dosage of ω-3
supplementation. The results of current meta-analysis study support the use of ω-3 PUFA 
supplementation for the improvement of the evaluated parameters in psoriatic patients. However, 
well-controlled and randomized studies are needed to confirm the veracity of non-significant 
and/or equivocal findings. 
Keywords: psoriasis, polyunsaturated fatty acids, PUFA, meta-analysis 
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Introduction: 
Psoriasis is the most common autoimmune and chronic inflammatory, proliferative skin disorder 
[1-3]; whilst its’ prevalence is asserted to range from 0.1%to 11.8% in various populations, with 
an average of 2–3%[3]. Psoriatic lesion involves epidermal keratinocytes and leukocyte cells [2],
and is characterized, classically, by sharply demarcated, red indurated plaques over the extensor 
surfaces of the body and scalp, accompanied by silvery white scales [3, 4]. Whilst there exists a 
component of heritability to psoriasis susceptibility, the inflammatory reaction is modulated by 
diet, lifestyle and environmental factors, such as infections and stress [1, 2, 5].
Topical medications are the first line treatment approach prescribed for patients with mild to 
moderate psoriasis [2, 5]. Typical treatments include various compounds, such as; vitamin D 
analogs, corticosteroids, dithranol, coaltar, and retinoids. However, may confer substantial, 
negative side-effects, including; hypercalcemia, skin irritation, cloth staining, teratogenicity and 
causes a burning sensation. The second approach includes systemic treatment methods such as 
cyclosporine and fumaric acid esters, notwithstanding observed side effects, including;
nephrotoxicity, hypertension, slow onset of action, diarrhea, lymphopenia, bone marrow 
suppression, nausea and hepatic fibrosis [1, 2, 5]. Therefore, given the deleterious side effects 
associated with traditional psoriatic therapies, it is imperative that contemporary, less injurious, 
treatments be investigated. Polyunsaturated fatty acids (PUFAs) are among such compounds 
which are showing potential as a safe, adjunctive treatment for many skin disorders, including
psoriasis [1-3, 5, 6]. The abnormal keratinocyte hyperproliferation in psoriasis arises due to the 
activation of T-cells, which subsequently produces the rich amount of arachidonic acid, leading 
to the generation of various proinflammatory mediators, including; PGs, LTs, cytokines and 
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adhesion molecules via MAPK/AP-1, EARK1/2 and protein kinase – C (PKC) activation 
pathways [1-3, 5].
Omega (ω) - 3 fatty acids (i.e., EPA and DHA) supplementation, in a dose-dependent manner,
results in inhibition of various pro-inflammatory mediators and metabolization of EPA and DHA 
leads to dampening of inflammation and higher resolution of the skin abnormalities[1-3, 5].
These have recently been used alone, or in combination with other drugs, in the treatment of 
psoriasis, [5].
So far, many studies have been conducted with the aim of investigating the effect of ω-3 on 
psoriasis. For example, an animal study, conducted by Qin et al, to evaluate the effect of omega 
3 on psoriasis [6], and asserted ω-3 to elicit mechanistic influence on psoriasis related 
inflammation, namely through its down-regulation of T-helper cells, interleukin (IL)-17, IL-22,
IL-23, and stimulation of regulatory T-cells [6]. Furthermore, in recent years, many randomized 
controlled trials have been performed on the efficacy and mechanism of action of ω-3
polyunsaturated fatty acids (n-3 PUFAs) on psoriasis. For example, Upala et al. conducted a 
systematic review of the effects of n-3 PUFAs on psoriasis [5], and although some studies found 
that n‐3 PUFAs were associated with improvements in the clinical Psoriasis Area and Severity 
Index (PASI) score, erythema, scaling, itching, area involved and infiltration; numerous studies 
did not find any reduction in scaling, erythema, area involved or thickness in the treatment group 
[5]. Therefore, given the potential to aid clinical treatment, yet equivocal nature of findings in 
the literature, the aim of this meta-analysis was to assess the efficacy of ω-3 fatty acids, as a
monotherapy, in treating patients with psoriasis. 
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Methods and Materials: 
Search strategy 
The present systematic review and meta-analysis was conducted according to the PRISMA 
guidelines [7]. We searched through different databases including ISI web of science, 
Pubmed/Medline™, Scopus™, EMBASE and Cochrane library™ up to November 2018 using 
the following MeSH and non-MeSH terms in titles and abstracts: (“fish oil” OR “omega 3” OR 
“ω-3” OR “EPA” OR “DHA” OR “fatty acid”) AND (“psoriasis”). Moreover, references of 
retrieved articles and previous related reviews were also examined to find eligible studies. 
Study selection 
All published studies were included for meta-analysis if they met the following criteria: 1) 
Randomized controlled clinical trials with designation of either parallel or cross-over comparing 
ω-3 PUFA treatment with placebo treatment in patients with psoriasis, 2) providing adequate 
information upon the baseline and endpoint scores of one of the psoriasis indices, including 
PASI score (as a tool for measuring the severity and extent of psoriasis by assessing the intensity 
and affected areas in the head and neck, upper limbs, trunk, and lower limbs), %TBSA (percent 
total body surface area affected) and subjective reports of disease progression (e.g., erythema, 
itching, scaling, infiltration and desquamation), with SEM, SD, or 95% CI for intervention and 
control groups, 3) the study with a proper controlled design where the difference between the 
intervention and control group was ω-3 PUFA supplementation. We considered the following 
criteria as the exclusion criteria: 1) non-human studies, 2) lack of a control group for ω-3
supplementation, 3) non-original and/or RCT studies including cohort, case-control, or cross-
sectional, reviews, letters, case reports and commentaries.
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Quality assessment 
The quality of studies were estimated using the Jadad score which includes the following items:
(1) randomization (one point for stating random allocation and additional point for describing the 
method appropriately), (2) blinding (One point for stating that the trial was blinded and 
additional point for describing the blinding method appropriately; One point was withdrawn if 
the method of randomization/blinding was inappropriate), and (3) reporting of number and 
reasons of withdrawals (one point for reporting of number, reasons and fate of dropouts). The 
possible score varies between 0 and 5, in which a score of ≥3 indicated higher quality studies and 
a score of less than 3 is considered as the low-quality study [8].
Data extraction 
The titles and abstract of included studies were reviewed independently by two authors (M.N)
and (M.T). Differing decisions were resolved by consulting a third reviewer (SJ). We retrieved 
the full-text papers for those that were potentially relevant to the subject of our study in the 
initial screening. The data extracted from the included trials were: year of study, study design,
location of conducted trial, sample size of intervention/control groups, participants 
characteristics (gender and age), duration of follow up, clinical condition of participants, dosage 
of intervention supplementation and reported significant outcomes. 
If the papers contained inadequate details, we planned to contact the authors to obtain the 
missing information. Where this was unsuccessful, we planned to calculate the missing data from 
the raw numbers and P-values reported. 
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Statistical analysis 
variable effects were defined as the weighted mean difference (WMD) with 95% confidence 
interval (CI) and the corresponding standard deviation (SD) in any of the psoriasis indices 
values. In case of not reporting the SD values, we calculated the SD from standard errors, P 
values, 95% CIs, or by converting the median and interquartile range to mean and SE using 
available formulas. We assessed the I2 index and χ2 test on Cochrane’s Q statistic to quantify the 
extent of heterogeneity, in which P<0.05 or I2>50% was defined as heterogeneous. A random-
effects model was used to pool the effect size if significant heterogeneity was indicated between 
studies. Otherwise, a fixed-effects model was used. We used Funnel plots, Begg’s rank 
correlation test, and Egger’s weighted regression test to examine any potential publication biases. 
To identify any potential heterogeneity source, we conducted sensitivity, stratified and meta-
regression analyses in accordance with the Cochrane guidelines [9].
All analyses were performed in Review Manager Software (Review Manager 5.3; Cochrane 
Collaboration, Oxford, England) and Comprehensive Meta-Analysis (version 3.2; Biostat). A P-
value of less than 0.05 was considered as statistically significant. 
Results: 
Literature search and selection of studies 
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The flow diagram of study selection was shown in Figure 1. A total number of 87 studies were 
initially identified after duplicates had been removed. In the next step, 74 more studies were 
excluded due to the following reasons: experimental studies (in-vitro or non-human trials) 
(n=61), non-clinical studies (reviews, editorials, letters and case reports) (n=13). Therefore, 13
possibly relevant studies were deemed for full text review. After screening, three articles were 
excluded because they: 1) did not administer ω-3 as the intervention, or administered as a 
combined supplementation; 2) insufficient reported data of psoriasis indices in the baseline and 
the end of follow up. An eventual 10 studies involving 560 participants were considered as 
eligible for inclusion in the present meta-analysis 
Study characteristics and quality assessment 
Characteristics of the included studies is presented in Table 1. In total, 10 RCTs [1, 3, 10-17]
were included in the meta-analysis, comprising a total of 278 individuals in the intervention 
group and 282 in the control group. Patients treated in these RCTs had psoriasis [3, 10-17] 
except for one in which the patients were obese with psoriasis disease[1]. Nine studies were 
published in English and the remaining one in Polish[3]. Study duration ranged from 4 to 48
weeks with a median of 8 weeks. The dosage of ω-3 supplementation was between 240 mg/day 
to 3600 mg/day with the median of 1800 mg/day EPA. The studies supplied ω-3 interventions 
with different forms including EPA [11], EPA and DHA [3, 10, 12-17] and α-linolenic acid 
(ALA)[1]. All included studies were published between 1988 to 2017 and had been conducted in 
India (n=1) [3], Spain (n=1) [10], Great Britain (n=1) [11], Norway(n=1) [12], Argentina (n=1) 
[13], Germany (n=1) [14], Italy (n=1) [1], US (n=2) [15, 16] and Scotland (n=1) [17]. There 
were no reports of serious adverse effects and only slight abdominal distress was reported in the 
reviewed papers.
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Table 2 presents the results of the study quality assessment. According to the previous studies, 
which indicated the studies with Jadad score of more than 3 as high quality studies, Most
included studies (7 of 10 studies) showed higher quality [1, 11, 12, 14-17] and the remaining 3 
studies considered as low methodologic quality [3, 10, 13].
Effect of ω-3 PUFA supplementation on PASI score 
Three studies reported data on PASI improvement [1, 3, 10] with no observed heterogeneity 
among these studies (P = 0.64, I² = 0%). The meta-analysis of the included trials indicated a 
significant reduction in PASI score by −1.58 [95% CI: -2.24, -0.92; Test for overall effect: Z = 
4.69 (P < 0.00001)] in favor of ω-3 PUFA group with the standardized mean difference (SMD) 
and 95% CI of -0.56 [-0.83, -0.28] (Figure 2-a).
Effect of ω-3 PUFA supplementation on erythema 
Eight studies had sufficient data for inclusion in meta-analyses erythema [3, 10-16]. There was 
significant heterogeneity between these studies (P <0.00001, I² = 99%). The random-effect 
model showed a statistically significant beneficial effect of ω-3 PUFA supplementation on
reducing erythema by -1.66 unit [(95% CI:-2.52, -0.81; Test for overall effect: Z = 3.82 (P 
=0.0001]. The pooled SMD and 95% CI were -1.55 [-2.47, -0.62] (Figure 2-b).
Effect of ω-3 PUFA supplementation on itching 
Five studies had sufficient data for inclusion in meta-analyses of itching[1, 11, 13, 16, 17].
Significant heterogeneity among trials was observed for itching (P <0.00001, I² = 94%). The
random-effect model did not indicate any significant pooled WMD favoring ω-3 PUFA 
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supplement versus control for itching [WMD: 0.25, 95% CI: -0.65, 1.15; Test for overall effect: 
Z = 0.55 (P = 0.58)] (Figure 2-c).
Effect of ω-3 PUFA supplementation on %TBSA 
Four studies had sufficient data for inclusion in meta-analyses of %TBSA with a significant 
observed heterogeneity among these studies (P <0.00001, I² = 99%%)[3, 11, 12, 15]. The
random-effect model did not show a significant pooled WMD favoring ω-3 PUFA supplement 
versus control for %TBSA [WMD: -7.40, 95% CI: -16.75, 1.95; Test for overall effect: Z = 1.55 
(P = 0.12)] (Figure 2-d).
Effect of ω-3 PUFA supplementation on scaling 
Five studies had sufficient data for inclusion in meta-analyses of scaling [10, 11, 13, 15, 16]. We 
found a statistically significant heterogeneity among the trials for scaling (P <0.00001, I² = 98%). 
The random-effect model revealed a significant pooled WMD for the efficacy of ω-3 PUFA 
supplementation on reducing scaling [WMD: -0.69, 95% CI: -1.26, -0.13; Test for overall effect: 
Z = 2.41 (P = 0.02)] with the pooled SMD of -2.06 [-3.66, -0.46] (Figure 2-e).
Effect of ω-3 PUFA supplementation on desquamation and infiltration 
Four and 3 studies had sufficient data for inclusion in meta-analyses of desquamation [3, 12, 14, 
16] and infiltration[12, 14, 16], respectively. The observed heterogeneity between studies for 
both desquamation and infiltration was statistically significant (P <0.00001, I² = 97%). The 
random-effect model did not show a significant net change for the efficacy of ω-3 PUFA 
supplementation on improving desquamation and infiltration [desquamation WMD: -0.33, 95%
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CI: -1.35, 0.69; Test for overall effect: Z = 0.64 (P = 0.52); infiltration WMD: -0.31, 95% CI: -
0.82, 0.20; Test for overall effect: Z = 1.19 (P = 0.24)] (Figures 2-f, 2-g).
Subgroup analyses 
The results of subgroup analyses are presented in Table 3. To evaluate the influence of ω-3
PUFA supplementation on the complications of psoriasis, included studies were divided into two 
distinct subgroups according to dosage of supplementation (<1800 vs. ≥1800 mg/day) and 
duration of study (≤8 vs. >8 weeks). Test of interaction showed significance for the subgroup 
differences regarding to ω-3 PUFAs’ dosage of ≥1800 mg/day. Significant improvements in
erythema, itching and scale were observed in the trials which used the higher-dosage of ω-3
supplementation with a significant reduction of heterogeneity in the scale index. Although, the 
lower-dosage of ω-3 PUFA supplementation and different duration of studies showed significant 
improvements in some indices, the between study heterogeneities are significant and robust 
(Table 3).
Sensitivity analysis 
Influence analysis was performed to examine the effect of each study on the estimated pooled 
effect size. Results of systematic removal of each study did not influence the overall weighted 
mean difference of ω-3 PUFA supplementation on erythema, which ranged from -0.54 (95% 
CI=-0.95, -0.13) to -1.96 (95% CI=-3.12, -0.80) (Figure 3).
Meta regression 
A meta-regression analysis was conducted to investigate the effect of different modulators in 
determining the heterogeneity of estimates. In accordance with subgroup analysis, higher-dosage 
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of ω-3 PUFA supplementation and lower duration of supplementation were significantly 
associated with the improvement in both erythema (dosage of ω-3 PUFA supplementation slope: 
−0.0007; 95% CI: −0.0005, -0.0006; p<0.001, Figure 4a-1; duration of supplementation slope: 
0.05; 95% CI: 0.03, 0.06; p<0.001, Figure 4a-2) and scale complications (dosage of 
supplementation slope: −0.0004; 95% CI: −0.00053, 0.00032; p<0.001, Figure 4b-1; duration of 
supplementation slope: 0.05; 95% CI: 0.03, 0.07; p<0.001, Figure 4b-2), whereas lower duration 
of supplementation were not associated with the improvement in PASI score.
Publication bias 
Among the main outcomes, erythema was selected as a representative index for assessing 
publication bias, as most of the included studies measured erythema as one of the psoriasis 
complications. Begg’s rank correlation (Kendall’s Tau with continuity correction: -0.39; z=1.36;
two-tailed p= 0.17) and Egger’s linear regression test (intercept: -12.7; standard error: 5.25; 95% 
CI: -25.6, 0.06; t= 2.43, df=6; two-tailed p= 0.06) did not indicate statistically significant 
publication bias for erythema outcome. This was confirmed according to the symmetric visual 
inspection of the corresponding funnel plot (Figure 5).
Discussion 
Whilst animal studies have routinely purported the therapeutic effect of ω-3 fatty acids on
psoriasis, human-based studies are much more equivocal in their conclusions. We therefore 
sought to conduct a meta-analysis to assess the efficacy of ω-3 fatty acids, as a monotherapy, in
treating patients with psoriasis. In accord with the aim of this study, our key findings were that
ω-3 PUFA supplementation, as a monotherapy, elicited significant reductions in PASI score, 
erythema, and scaling. Furthermore, our-subgroup analysis highlighted that ω-3 supplementation 
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with dosages of >1800mg/day and >8weeks in duration were associated with more beneficial 
outcomes. 
The PASI score is a subjective assessment based on estimation by clinicians. Studies have shown 
that it can be unreliable due to its complex score calculation, it can be difficult to interpret due to 
its non-linearity and the amount of improvement in the score does not always correspond to 
clinical relevance. Furthermore, the PASI score does not take into account the disproportionate 
disease burden reflected in the more visible (hands, feet, nails, face) or covered (genitalia and 
perianal) body regions, or the impact on patient quality of life. Specifically relating to PASI 
score, three studies reported such data [1, 3, 10]. ω-3 PUFAs, in general, are considered to 
modify inflammatory and immune reactions; moreover, ω-3 PUFAs have direct effects on 
reducing body weight and fat deposition via effects on lipid metabolism-related genes [18] 
offering a conceivable explanation as to why PASI score may be reduced following a period of 
supplementation. Of importance is what, practically, demarcates a clinically meaningful 
improvement. Currently, it is reported that for clinically meaningful improvement in psoriatic 
patients is at least 50–75% improvement, which has been subsequently translated into 50–75%
improvement in the PASI score[19]. Notwithstanding the difficulties in interpreting PASI score, 
this meta-analysis has highlighted the significant improvements manifest through ω-3 PUFA 
monotherapy, and therefore warrants consideration in prescribed treatment by clinicians. 
The levels of arachidonic acid (AA) and its metabolites, particularly leukotriene B4 (LTB4) and 
12-hydroxyeicosatetraenoic acid (12-HETE), are higher in psoriatic plaques than in clinically 
uninvolved skin [15]. Both LTB4 and 12-HETE are chemotactic for neutrophils, leading to the 
contemporary use of n-3 PUFAs as an adjunct therapy because their anti-inflammatory and/or 
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antichemotactic properties seem to induce a protective effect against cutaneous diseases, 
including psoriasis [17], which has been avowed in the present meta-analysis. Furthermore, 
Bitteiner [11] assert that since stable plaque psoriasis improves significantly with PUFA 
supplementation, more profound effects are likely in the inflammatory unstable variants such as
erythrodermic psoriasis. This assertion was supported in eight studies included in this meta-
analysis [3, 10-16], yielding a statistically significant beneficial effect of ω-3 PUFA 
supplementation, reducing erythema by -1.66 units. Five studies in this meta-analysis [10, 11, 13, 
15, 16] reported that ω-3 PUFA supplementation significantly reduced scaling, and has been 
suggested that concomitant reduced inflammatory markers in ω-3 PUFA supplementation groups
may be mediating such positive changes. Grimminger et al. [14], for example, measured the level 
of leukotriene B4 and B5, platelet-activating factor (PAF) and 5-HETE. They reported a sharp 
increase in the generation of LTB5 and 5-HEPE starting from day 3 to day 10 of n-3 PUFA 
infusion, indicating the reduction of chemotactic and neutrophil activation. 
Of note, whilst our meta-analyses highlighted significant improvements in a number of variables,
supplementation with ω-3 PUFA did not result in any significant improvements in itching, 
%TBSA, or desquamation and infiltration. The reason for no significant effect manifest in this 
meta-analysis stems from the starkly contrasting, and equivocal results in the included studies. 
Recently, and similarly, Upala et al [5], in their systematic review, noted ω -3 PUFAs were 
associated with improvements in the PASI score, erythema, scaling, itching, area involved and 
infiltration; however, some studies did not find reduction in scaling, erythema, area involved or 
thickness in the treatment group. By conducting the present meta-analysis, we have elucidated 
the current evidence for the effectiveness of ω-3 PUFA supplementation on PASI score, 
erythema and scaling; however, it is evident that more well-controlled studies specifically 
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investigating itching, %TBSA, or desquamation and infiltration are needed to facilitate a more 
definitive conclusion. 
Interestingly, significant improvements in erythema, itching and scale were observed more
readily in the trials which used ω-3 supplementation dosages >1800mg/day (Table 3). This 
finding necessitates further work to ascertain the optimal dosing of ω-3 for it to confer 
significant benefits. 
Strengths and Limitations 
The primary strength of this study was that this is the first meta-analysis to assess the impact of 
ω-3 supplementation on the severity of Psoriasis, manifest in human-based RCTs; and given the 
potential influence on clinical practice, this is a major finding. The evidence base, prior to this 
meta-analysis, was bereft of uniformity, and urgently required a summative, quantitative 
assessment, which we have provided. We demonstrated that there is sufficient evidence for ω-3
supplementation to elicit positive effects on PASI score, erythema and scaling. Another strength 
of the current meta-analysis is the assimilation of the heterogeneous sample of participants, with 
a range of demographic status’, ethnicities and ages. We were also able to stratify analyses based 
on both duration of supplementation and dosage, giving clinicians foresight into expected 
outcomes based on such information. 
Notwithstanding, the current study has some limitations worth considering. A large number of 
included trials were small in sample size, and it has been asserted by Sterne et al. that it is 
probable for studies with small sample sizes to report bigger effect sizes in intervention arms 
than studies with larger participant pools[20], nevertheless, this was out of the operational 
control of the meta-analysis. A further limitation of the present study was the paucity of eligible 
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studies, highlighting the need for more, high-quality RCT’s. A further potential limitation is the 
plethora of controlling treatments administered across the included studies; although our meta-
analysis showed, for some variables, ω-3 is significantly better vs. control groups, the controls 
varied from topical paraffin, talcalcitol, various oils, and medications; conceivably influencing 
the strength of results found. Therefore, the authors recommend that in addition to further RCTs 
being conducted, studies should contain at least one standardized control-arm. 
Conclusion 
The results of current meta-analysis study support the use of ω-3 PUFA supplementation, as a 
monotherapy, for the improvement of PASI score, erythema and scaling in psoriatic patients. 
However, the literature base remains equivocal as to whether significant benefits are incurred for 
itching, %TBSA, or desquamation and infiltration. Therefore, notwithstanding the positive effect 
elicited by ω -3 PUFA supplementation for some clinically relevant variables, it is evident that 
more, well-controlled and randomized studies are needed to confirm the veracity of non-
significant and/or equivocal findings. 
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Figure 1: Flow diagram of article selection process 
Figure 2 : Forest plots of analysis of effect of ω-3 supplementation on psoriasis indices including 
A)PASI, B) erythema, C) itching, D) %TBSA, E) scale, F) desquamation and G) infiltration. Random 
effects model was used to pool the mean change of indicators. CI, confidence interval; I-squared 
inconsistency; Abbreviations: PASI, Psoriasis Area Severity Index; %TBSA, percent total body surface 
area 
Figure 3: Sensitivity analysis for the effect of ω-3 supplementation on erythema 
Figure 4a: Meta-regression bubble plots of the association between mean changes in erythema score and 
1) dosage of ω-3 supplementation, 2) duration of supplementation. 
Figure 4b: Meta-regression bubble plots of the association between mean changes in scale score and 1) 
dosage of ω-3 supplementation, 2) duration of supplementation. 
Figure 5: Funnel plot detailing publication biases in all included trials. 
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